Proactive Investors - Run By Investors For Investors

Neurotrope raising US$15.3mln to fund Alzheimer’s drug trial

It could be the first step in raising a total of around US$150mln and it will support a Phase 2b clinical trial
Neurotrope raising US$15.3mln to fund Alzheimer’s drug trial
If all warrants were exercised Neurotrope would raise US$136mln on top of the initial US$15.3mln funding

Neurotrope (OTCMKTS:NTRP) told investors it is raising US$15.3mln to fund the clinical development of its potential Alzheimer’s drugs.

It is part of a series of share issues - via conversion of preferred stock and/or warrants – that could see more than US$100mln of additional funding for the group.

Cash raised will support a Phase 2b clinical trial, which will study 150 patients with moderately severe to severe Alzheimer's disease.

The company has an exclusive license to develop and commercialize bryostatin, which is described as a ‘potent modulator’ of an enzyme call protein kinase C epsilon (PKCe).

PKCe deficit is seen as a potential cause of Alzheimer’s disease. Neurotrope highlights that in animal research the activation of PKCe has shown to improve learning and memory. It also highlighted that PKCe has been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a possible treatment of cognitive disorders.

Initially, the company’s private placement will result in the raise of US$15.3mln with units sold to investors at 60 American cents each. Each unit will comprise one one-hundredth of a preference share (which can be converted later into common stock) and five separate share warrants.

If all warrants were exercised Neurotrope would raise US$136mln on top of the initial US$15.3mln funding.

Subscribers in the private placing will also be given the right to participate in any future equity financings over the next year.

View full NTRP profile View Profile

Neurotrope Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
May 09 2019
Here we take a look under the hood of Shield Therapeutics

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use